More information soon.


MiRXES is a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, and has operations in China, Japan and the United States, as well as commercial activities in over 45 countries globally. Founded in 2014 as a spin-off from Agency of Science, Technology and Research, MiRXES has strong pipelines in multiple cancer types including lung, colorectal, liver, pancreatic, breast cancers, and in cardiovascular, metabolic and infectious diseases. In 2019, MiRXES launched GASTROClear, the world’s first microRNA blood test for early detection of gastric cancer. In 2020, MiRXES mass produced the Fortitude Kit, Singapore’s first authorized COVID-19 RT-PCR test, and has since deployed more than 8 million kits globally. MiRXES believes the future of healthcare will shift from treating the sick to preventive healthcare, and is committed to changing lives by delivering preventive healthcare solutions to all via its science and innovation.